Should I buy or sell Addex Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Addex Therapeutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ADXN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADXN, but not buy additional shares or sell existing shares. View ADXN analyst ratings or view top-rated stocks .

How have ADXN shares performed in 2024?

Addex Therapeutics' stock was trading at $6.05 on January 1st, 2024. Since then, ADXN shares have increased by 230.6% and is now trading at $20.00. View the best growth stocks for 2024 here .

Are investors shorting Addex Therapeutics?

Addex Therapeutics saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 8,700 shares, a drop of 26.9% from the March 15th total of 11,900 shares. Based on an average daily trading volume, of 17,000 shares, the short-interest ratio is presently 0.5 days. Currently, 0.9% of the shares of the company are short sold. View Addex Therapeutics' Short Interest .

When is Addex Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ADXN earnings forecast .

How were Addex Therapeutics' earnings last quarter?

Addex Therapeutics Ltd (NASDAQ:ADXN) released its quarterly earnings results on Thursday, November, 4th. The company reported ($14.40) earnings per share for the quarter, meeting the consensus estimate of ($14.40). The company had revenue of $0.83 million for the quarter, compared to analyst estimates of $0.42 million. Addex Therapeutics had a negative trailing twelve-month return on equity of 236.83% and a negative net margin of 550.78%. During the same quarter last year, the firm posted ($15.60) earnings per share.

When did Addex Therapeutics' stock split?

Addex Therapeutics's stock reverse split before market open on Monday, October 23rd 2023. The 1-20 reverse split was announced on Monday, October 23rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Addex Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Addex Therapeutics investors own include Achillion Pharmaceuticals (ACHN) , ACADIA Pharmaceuticals (ACAD) , Arbutus Biopharma (ABUS) , Abacus Property Group (ABP) , Advanced BioMedical Technologies (ABMT) , Abiomed (ABMD) , ARCA biopharma (ABIO) , Abeona Therapeutics (ABEO) and Abcam (ABCZY) .

How do I buy shares of Addex Therapeutics?

Shares of ADXN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ADXN

Addex Therapeutics (ADXN) Stock Price, News & Analysis

→ This company has increased its dividend every year for 54 years (From DTI) (Ad)

Free ADXN Stock Alerts

$20.00

-0.96 (-4.58%)

(As of 10:34 AM ET)

Compare

Today's Range: $19.87
▼
$20.60
50-Day Range: $8.96
▼
$27.90
52-Week Range: $5.00
▼
$27.90

Volume: 3,102 shs
Average Volume: 16,907 shs
Market Capitalization: $21.20 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Addex Therapeutics alerts:

Addex Therapeutics MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
0.85% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.51
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($17.20) to ($11.80) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.75 out of 5 stars

Medical Sector

844th out of 918 stocks

Pharmaceutical Preparations Industry

390th out of 424 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Addex Therapeutics.

5.0

Short Interest

Percentage of Shares Shorted
0.85% of the float of Addex Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Addex Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Addex Therapeutics has recently decreased by 26.89%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Addex Therapeutics does not currently pay a dividend.
Dividend Growth
Addex Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ADXN.

2.5

News and Social Media Coverage

News Sentiment
Addex Therapeutics has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Addex Therapeutics this week, compared to 0 articles on an average week.
Search Interest
1 people have searched for ADXN on MarketBeat in the last 30 days.
MarketBeat Follows
Only 1 people have added Addex Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Addex Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
15.00% of the stock of Addex Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 16.14% of the stock of Addex Therapeutics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Addex Therapeutics are expected to grow in the coming year, from ($17.20) to ($11.80) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Addex Therapeutics is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Addex Therapeutics is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Addex Therapeutics has a P/B Ratio of 2.50. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

This company has increased its dividend every year for 54 years

There are three basic steps to building the Ultimate Dividend Portfolio. Step #1 is to Get The High Yields! So an index fund like the SPY, paying only 1.5% a year, isn’t going to cut it. But a company like Altria Group (MO) will.

Click here to get them (for Free).

About Addex Therapeutics Stock (NASDAQ:ADXN)

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for pain, anxiety, and addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

ADXN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ADXN Stock News Headlines

April 19, 2024 | globenewswire.com

Addex to Present at the Swiss Biotech Day 2024

April 18, 2024 | investorplace.com

ADXN Stock Earnings: Addex Therapeutics Reported Results for Q4 2023

April 19, 2024 | The Bull Report (Ad)

Healthcare Takes A Big Step Forward With The Help Of AI

The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.

April 18, 2024 | seekingalpha.com

Addex Therapeutics GAAP EPS of -CHF 0.14, revenue of CHF 1.65M

April 18, 2024 | globenewswire.com

Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update

April 12, 2024 | americanbankingnews.com

Addex Therapeutics Ltd (NASDAQ:ADXN) Short Interest Update

April 11, 2024 | globenewswire.com

Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024

April 3, 2024 | finanznachrichten.de

Neurosterix launches with $63M to Advance Allosteric Modulator Therapeutics for Neurological Disorders

April 19, 2024 | The Bull Report (Ad)

Healthcare Takes A Big Step Forward With The Help Of AI

The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.

April 3, 2024 | markets.businessinsider.com

Addex Announces Launch Of Neurosterix In Partnership With Perceptive - Quick Facts

April 3, 2024 | globenewswire.com

Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders

March 14, 2024 | globenewswire.com

Addex to Present at the Bio-Europe Spring 2024 Conference

February 22, 2024 | benzinga.com

Addex Therapeutics Stock (NASDAQ:ADXN), Short Interest Report

January 31, 2024 | finance.yahoo.com

Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.

January 9, 2024 | finance.yahoo.com

Addex to Present at the Swiss Equities Baader Conference

January 5, 2024 | finance.yahoo.com

Addex to Present at Biotech Showcase™ 2024

December 23, 2023 | thestreet.com

Addex Therapeutics Ltd

December 20, 2023 | finanznachrichten.de

Addex Therapeutics: Addex Shareholders Approve All Resolutions at Extraordinary General Meeting

December 20, 2023 | finance.yahoo.com

Addex Shareholders Approve All Resolutions at Extraordinary General Meeting

December 14, 2023 | finance.yahoo.com

Addex Creates Treasury Shares

November 29, 2023 | msn.com

Addex Therapeutics GAAP EPS of -CHF0.03, income of CHF0.33M

November 29, 2023 | markets.businessinsider.com

Addex Therapeutics Posts Narrower Loss In Q3 - Quick Facts

November 29, 2023 | finance.yahoo.com

Addex Reports Q3 2023 Financial Results and Provides Corporate Update

November 28, 2023 | finance.yahoo.com

Addex Convenes Extraordinary General Meeting

November 23, 2023 | finance.yahoo.com

Addex Therapeutics to Release Third Quarter 2023 Financial Results and Host Conference Call on November 29, 2023

November 14, 2023 | finance.yahoo.com

Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients

November 2, 2023 | finance.yahoo.com

Addex Announces Participation in the Bio-Europe 2023 Conference

See More Headlines

Receive ADXN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Addex Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/04/2021
Today: 4/19/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ADXN
CUSIP: N/A
CIK: 1574232
Web: www.addextherapeutics.com
Phone: 011-41-22-884-1555
Fax: 41-22-884-1556
Employees: 24
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($19.27)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-21,800,000.00
Net Margins: -550.78%
Pretax Margin: -549.49%
Return on Equity: -236.83%
Return on Assets: -147.15%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.97
Quick Ratio: 2.97

Sales & Book Value

Annual Sales: $1.51 million
Price / Sales: 14.71
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $8.01 per share
Price / Book: 2.62

Miscellaneous

Outstanding Shares: 1,060,000
Free Float: 901,000
Market Cap: $22.22 million
Optionable: Not Optionable
Beta: 1.66

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Timothy Mark Dyer (Age 56)
Co-Founder, CEO & Director
Dr. Roger G. Mills M.D. (Age 67)
Chief Medical Officer & Director
Mr. Lénaic Teyssédou (Age 38)
Head of Finance
Dr. Jean-Philippe Rocher Ph.D. (Age 65)
Head of Discovery - Chemistry
Dr. Robert Lutjens (Age 56)
Head of Discovery - Biology
Dr. Mikhail Kalinichev Ph.D. (Age 57)
Head of Translational Science

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ADXN Stock Analysis - Frequently Asked Questions

Should I buy or sell Addex Therapeutics stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Addex Therapeutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ADXN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADXN, but not buy additional shares or sell existing shares.
View ADXN analyst ratings or view top-rated stocks.
How have ADXN shares performed in 2024?: Addex Therapeutics' stock was trading at $6.05 on January 1st, 2024. Since then, ADXN shares have increased by 230.6% and is now trading at $20.00.
View the best growth stocks for 2024 here.
Are investors shorting Addex Therapeutics?: Addex Therapeutics saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 8,700 shares, a drop of 26.9% from the March 15th total of 11,900 shares. Based on an average daily trading volume, of 17,000 shares, the short-interest ratio is presently 0.5 days. Currently, 0.9% of the shares of the company are short sold.
View Addex Therapeutics' Short Interest.
When is Addex Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ADXN earnings forecast.

How were Addex Therapeutics' earnings last quarter?: Addex Therapeutics Ltd (NASDAQ:ADXN) released its quarterly earnings results on Thursday, November, 4th. The company reported ($14.40) earnings per share for the quarter, meeting the consensus estimate of ($14.40). The company had revenue of $0.83 million for the quarter, compared to analyst estimates of $0.42 million. Addex Therapeutics had a negative trailing twelve-month return on equity of 236.83% and a negative net margin of 550.78%. During the same quarter last year, the firm posted ($15.60) earnings per share.
When did Addex Therapeutics' stock split?: Addex Therapeutics's stock reverse split before market open on Monday, October 23rd 2023. The 1-20 reverse split was announced on Monday, October 23rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
What other stocks do shareholders of Addex Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Addex Therapeutics investors own include Achillion Pharmaceuticals (ACHN), ACADIA Pharmaceuticals (ACAD), Arbutus Biopharma (ABUS), Abacus Property Group (ABP), Advanced BioMedical Technologies (ABMT), Abiomed (ABMD), ARCA biopharma (ABIO), Abeona Therapeutics (ABEO) and Abcam (ABCZY).
How do I buy shares of Addex Therapeutics?: Shares of ADXN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ADXN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial